INTRODUCTION {#sec1-1}
============

Thrombosis of mechanical prosthesis for aortic valve replacement is uncommon.\[[@ref1][@ref2]\] The bi-leaflet St. Jude Medical cardiac valve prosthesis is one of the most commonly used mechanical valve substitutes and has a special design, which provides nearly laminar flow, a low-pressure gradient, and a large effective orifice area resulting in reduced risk of thrombus formation.\[[@ref2]\]

CASE REPORT {#sec1-2}
===========

A 70-year-old man with history of calcified, rheumatic aortic stenosis who underwent aortic valve replacement 16 years ago (31-mm St. Jude Medical bi-leaflet mechanical valve prosthesis) developed severe shortness of breath in the last weeks. Additionally, he reported gastroenteritis few weeks ago. Clinical examination on admission showed orthopnoea, tachypnoea, tachycardia, and hypotension. Cardiac auscultation revealed systolic murmur and absence of the metallic click sound. The chest X-ray demonstrated enlargement of the heart \[[Figure 1](#F1){ref-type="fig"}\], and the echocardiography revealed dilation of the left ventricle and reduced contractility with an ejection fraction of 15%. Flow velocity over the prosthetic valve was 4 m/s in combination with severe regurgitation into the left ventricle. The International Normalized Ratio (INR) at admission was 2.3.

![Chest X-ray (anteroposterior view) demonstrating cardiomegaly](JCDR-3-228-g001){#F1}

The patient underwent emergency reoperation immediately. The mechanical aortic prosthesis showed complete immobilization of both leaflets due to thrombotic material located in both sides of the leaflets pivots \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. The mechanical valve was removed and a bio-prosthesis was implanted. Postoperative recovery was uneventful. Thrombotic material was sent for microbiological examination and there were no bacteria.

![Aortic view of the explanted aortic prosthesis showing complete immobilization of both leaflets due to thrombosis located in both areas of the leaflet pivots. The sewing ring was covered completely by "neointimal" tissue (is here partially removed), but there was no interaction between this tissue and the prosthesis leaflets](JCDR-3-228-g002){#F2}

![Ventricular view of the explanted aortic prosthesis showing the thrombosis of the leaflet pivots](JCDR-3-228-g003){#F3}

DISCUSSION {#sec1-3}
==========

Prosthetic valve thrombosis is the most serious thrombembolic complication with high mortality.\[[@ref1]\] The bi-leaflet mechanical St. Jude Medical valve prosthesis has a very low complication rate with a thrombosis rate of 0.03% per patient-year.\[[@ref3][@ref4]\] The two leaflet pivots of this prosthesis are designed within a "butterfly" recessed in the orifice ring without fixed pivot points. This allows rapid, controlled movement of the leaflets without the possibility to produce an area of stasis.\[[@ref2]\] Velocity and turbulent shear stress studies of this mechanical valve prosthesis found for the region adjacent to the pivot mechanism a combination of high turbulent shear stresses and flow separation.\[[@ref5]\] Nevertheless, larger valve size seems to be risk factor for the late thrombembolic event.\[[@ref1]\]

Because of early reports of leaflet entrapment due to small thrombus, anticoagulation is recommended for life.\[[@ref6]\] A decrease in anticoagulation or the absence of anticoagulation, even for short periods, was reported to be a significant risk factor for thrombembolic complication after valve replacement with the St. Jude Medical prosthesis.\[[@ref1][@ref7][@ref8]\] In the present case, the patient did not discontinue anticoagulation, the INR monitoring was performed by the family doctor every 3 to 4 weeks and was within the target range. Nevertheless, it is possible that during gastroenteritis the level was even lower but this is only speculation. Closer anticoagulation monitoring (e.g., once a week) could probably help to reduce risk of late prosthesis thrombosis.

Self-management of INR has been reported to result in better achievement of the target level.\[[@ref9]\] A prospective, randomized, and multicenter trial of self-management demonstrated the efficacy and safety of very low-dose INR (target range of 1.6-2.1 for aortic valve replacement).\[[@ref10]\]

Although most patients died of cardiac arrest or cardiogenic shock before any surgery or intervention,\[[@ref11]\] valve thrombosis does not cause sudden death.\[[@ref12]\] The clinical condition of the patients deteriorates over several days allowing time for diagnosis and specific treatment.\[[@ref11][@ref13]\] The operative risk remains acceptable even when the patient\'s clinical condition is severe. Satisfactory results have been reported after thrombolytic therapy for prosthetic valve thrombosis. Although severe complications during treatment have been reported to be transient, nonsurgical treatment is an alternative for valve thrombosis only when the patient\'s clinical condition is not critical.\[[@ref14][@ref15]\]

CONCLUSION {#sec1-4}
==========

This case illustrates the need for closer monitoring of the anticoagulation treatment in patients with large size prostheses after replacement of the aortic valve, even if the course after mechanical valve implantation is uneventful for many years. In case of suspected valve thrombosis, early diagnosis is recommended and emergency operation is indicated in patients with critical clinical condition.
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